Time spent outdoors is the best defence against rising rates of short-sightedness, but scientists are searching for other ways to reverse the troubling trend. Time spent outdoors is the best defence against rising rates of short-sightedness, but scientists are searching for other ways to reverse the troubling trend.
Dopavision has announced positive topline results from a proof-of-concept trial of MyopiaX, a noninvasive photobiomodulation intervention designed to slow myopia progression in children.“The 6-month outcomes represent a significant step in the clinical development of MyopiaX,” Ian Flitcroft, PhD, FRCOphth, coordinating investigator of the MyopiaX-1 trial, said in a company press
Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.